Xenon Pharmaceuticals Announced Two Oral Presentations For XEN1101 Clinical Data At AAN 2024 Annual Meeting
$XENE
Biotechnology: Pharmaceutical Preparations
Health Care
Xenon's Oral Presentations at AAN
Oral Presentation #005 (French et al.) "Interim, Long-term, Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults with Focal Epilepsy."
Session 19: Epilepsy Clinical Trials and Long-term Studies
Oral Presentation #004 (Porter et al.) "The Impact of Disease Severity on Responder Rates in a Phase 2b Study of XEN1101, a Potent, Selective Potassium Channel Opener, in Adults With Focal Epilepsy (X-TOLE)."
Session 19: Epilepsy Clinical Trials and Long-term Studies
Xenon is also hosting Booth #1797 in the AAN Exhibit Hall, which runs until Wednesday, April 17, 2024 at 4:00 pm MT.